Skip to main content
SpringerLink
Log in

Effect of β-Glucan on Drain Fluid and Amount of Drainage Following Modified Radical Mastectomy

  • Original Research
  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

Introduction

To reduce the seroma formation following mastectomy and axillary dissection, many different techniques and drugs have been investigated. The aim of this study is to evaluate the effects of oral β-glucan on drain fluid and efficacy of daily drainage and drain removal day in mastectomy patients.

Methods

One hundred and thirty breast cancer patients of Ankara Oncology Training and Research Hospital were divided into 2 groups by consecutive randomization (n = 65 each). β-glucan 10 mg capsules were administered to Group 1 twice a day for 10 days. Group 2 took placebos in the same manner. Age, menarche age, menopause, parity, history of oral contraceptives, comorbidities, postoperative daily drainage volumes and drain removal days were recorded and compared. Seroma samples during the first and second day of drainage were taken for analysis of Interleukin-6 (IL-6) and Tumor Necrosis Factor (TNF-α).

Results

There was no difference between groups in terms of age, menarche age, menopause period, parity, oral contraceptive use and comorbidities. Group 1 showed significantly lower daily drainage volumes between days 2 and 8. Mean drain removal day was 7.16 ± 1.72 in Group 1 and 8.59 ± 2.27 in Group 2. The difference was significant (p < 0.001). TNF-α and IL-6 levels on days 1 and 2 in Group 1 were significantly lower (p < 0.001). In addition, β-glucan significantly shortened the number of days required for the drain removal in patients who have comorbidities (p = 0.018). The earliest removal was in patients without comorbidity and who received β-glucan (p = 0.002).

Conclusion

β-glucan decreased drain discharges after mastectomy. The drains were removed earlier in β-glucan administered patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ooi VE, Liu F. Immunomodulation and anti-cancer activity of polysaccharide-protein complexes. Curr Med Chem. 2000;7:715–29.

    Article  CAS  PubMed  Google Scholar 

  2. Vetvicka V, Dvorak B, Vetvickova J, et al. Orally administered marine (1→3)-beta-d-glucan Phycarine stimulates both humoral and cellular immunity. Int J Biol Macromol. 2007;40:291–8.

    Article  CAS  PubMed  Google Scholar 

  3. Morikawa K, Takeda R, Yamazaki M, Mizuno D. Induction of tumoricidal activity of polymorphonuclear leukocytes by a linear beta-1,3-d-glucan and other immunomodulators in murine cells. Cancer Res. 1985;45:1496–501.

    CAS  PubMed  Google Scholar 

  4. Babineau TJ, Marcello P, Swails W, Kenler A, Bistrian B, Forse RA. Randomized phase I/II trial of a macrophage-specific immunomodulator (PGG-glucan) in high-risk surgical patients. Ann Surg. 1994;220:601–9.

    Article  CAS  PubMed  Google Scholar 

  5. Mansell PW, Ichinose H, Reed RJ, Krementz ET, McNamee R, Di Luzio NR. Macrophage-mediated destruction of human malignant cells in vivo. J Natl Cancer Inst. 1975;54:571–80.

    CAS  PubMed  Google Scholar 

  6. Goodridge HS, Wolf AJ, Underhill DM. Beta-glucan recognition by the innate immune system. Immunol Rev. 2009;230(1):38–50.

    Article  CAS  PubMed  Google Scholar 

  7. Wei D, Williams D, Browder W. Activation of AP-1 and SP1 correlates with wound growth factor gene expression in glucan-treated human fibroblasts. Int Immunopharmacol. 2002;2(8):1163–72.

    Article  CAS  PubMed  Google Scholar 

  8. Fadok VA, Bratton DL, Rose DM, Pearson A, Ezekewitz RA, Henson PM. A receptor for phosphatidylserine-specific clearance of apoptotic cells. Nature. 2000;405(6782):85–90.

    Article  CAS  PubMed  Google Scholar 

  9. Somers RG, Jablon LK, Kaplan MJ, Sandler GL, Rosenblatt NK. The use of closed suction drainage after lumpectomy and axillary node dissection for breast cancer. Ann Surg. 1992;215:146–9.

    Article  CAS  PubMed  Google Scholar 

  10. Pogson CJ, Adwani A, Ebbs SR. Seroma following breast cancer surgery. Eur J Surg Oncol. 2003;29:711–7.

    Article  CAS  PubMed  Google Scholar 

  11. Giuliano AE, McCall L, Beitsch P, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg. 2010;252(3):426–32; discussion 432–3.

    Google Scholar 

  12. Watt-Boolsen S, Nielsen VB, Jensen J, Bak S. Postmastectomy seroma. A study of the nature and origin of seroma after mastectomy. Dan Med Bull. 1989;36:487–9.

    CAS  PubMed  Google Scholar 

  13. Bonnema J, Ligtenstein DA, Wiggers T, van Geel AN. The composition of serous fluid after axillary dissection. Eur J Surg. 1999;165:9–13.

    Article  CAS  PubMed  Google Scholar 

  14. Moore MM, Freeman MG. Fibrin sealant in breast surgery. J Long Term Eff Med Implants. 1998;8:133–42.

    CAS  PubMed  Google Scholar 

  15. Burak WE Jr, Goodman PS, Young DC, Farrar WB. Seroma formation following axillary dissection for breast cancer: risk factors and lack of influence of bovine thrombin. J Surg Oncol. 1997;64:27–31.

    Article  CAS  PubMed  Google Scholar 

  16. Coveney EC, O’Dwyer PJ, Geraghty JG, O’Higgins NJ. Effect of closing dead space on seroma formation after mastectomy—a prospective randomized clinical trial. Eur J Surg Oncol. 1993;19:143–6.

    CAS  PubMed  Google Scholar 

  17. Galatius H, Okholm M, Hoffmann J. Mastectomy using ultrasonic dissection: effect on seroma formation. Breast. 2003;12:338–41.

    Article  PubMed  Google Scholar 

  18. Rice DC, Morris SM, Sarr MG, et al. Intraoperative topical tetracycline sclerotherapy following mastectomy: a prospective, randomized trial. J Surg Oncol. 2000;73:224–7.

    Article  CAS  PubMed  Google Scholar 

  19. Henry G, Garner WL. Inflammatory mediators in wound healing. Surg Clin North Am. 2003;83(3):483–507.

    Article  PubMed  Google Scholar 

  20. Grellner W, Georg T, Wilske J. Quantitative analysis of proinflammatory cytokines (IL-1beta, IL-6, TNF-alpha) in human skin wounds. Forensic Sci Int. 2000;113(1–3):251–64.

    Article  CAS  PubMed  Google Scholar 

  21. Lin E, Calvano SE, Lowry SF. Inflammatory cytokines and cell response in surgery. Surgery. 2000;127(2):117–26.

    Article  CAS  PubMed  Google Scholar 

  22. Gallucci RM, Simeonova PP, Matheson JM, et al. Impaired cutaneous wound healing in interleukin-6-deficient and immunosuppressed mice. FASEB J. 2000;14(15):2525–31.

    Article  CAS  PubMed  Google Scholar 

  23. Tokunaga A, Onda M, Fujita I, et al. Sequential changes in the cell mediators of peritoneal and wound fluids after surgery. Surg Today. 1993;23(9):841–4.

    Article  CAS  PubMed  Google Scholar 

  24. Ravanti L, Kähäri VM. Matrix metalloproteinases in wound repair (review). Int J Mol Med. 2000;6(4):391–407.

    CAS  PubMed  Google Scholar 

  25. Jain PK, Sowdi R, Anderson AD, MacFie J. Randomized clinical trial investigating the use of drains and fibrin sealant following surgery for breast cancer. Br J Surg. 2004;91:54–60.

    Article  CAS  PubMed  Google Scholar 

  26. McCaul JA, Aslaam A, Spooner RJ, Louden I, Cavanagh T, Purushotham AD. Aetiology of seroma formation in patients undergoing surgery for breast cancer. Breast. 2000;9:144–8.

    Article  CAS  PubMed  Google Scholar 

  27. Kocdor MA, Kilic Yildiz D, Kocdor H, et al. Effects of locally applied 5-fluorouracil on the prevention of postmastectomy seromas in a rat model. Eur Surg Res. 2008;40:256–62.

    Google Scholar 

  28. Firat C, Samdanci E, Erbatur S, et al. β-Glucan treatment prevents progressive burn ischaemia in the zone of stasis and improves burn healing: an experimental study in rats. Burns. 2013;39(1):105–12.

    Article  PubMed  Google Scholar 

  29. Caglayan K, Erdogan N, Avci B, Gungor B, Cinar H, Arslan N. Effect of β-glucan on intestinal anastomoses in a rat model. Adv Clin Exp Med. 2013;22(2):157–63.

    PubMed  Google Scholar 

  30. Gulmen S, Kiris I, Kocyigit A, Dogus DK, Ceylan BG, Meteoglu I. β-Glucan protects against lung injury induced by abdominal aortic ischemia-reperfusion in rats. J Surg Res. 2010;164(2):e325–32.

    Article  CAS  PubMed  Google Scholar 

  31. Berdal M, Appelbom HI, Eikrem JH, et al. Aminated β-1,3-d-glucan has a dose-dependent effect on wound healing in diabetic db/db mice. Wound Repair Regen. 2011;19(5):579–87.

    Article  PubMed  Google Scholar 

  32. Lee SB, Jeon HW, Lee YW, et al. Bio-artificial skin composed of gelatin and (1→3), (1→6)-beta-glucan. Biomaterials. 2003;24(14):2503–11.

    Article  CAS  PubMed  Google Scholar 

  33. Toklu HZ, Sener G, Jahovic N, Uslu B, Arbak S, Yeğen BC. Beta-glucan protects against burn-induced oxidative organ damage in rats. Int Immunopharmacol. 2006;6(2):156–69.

    Article  CAS  PubMed  Google Scholar 

  34. Portera CA, Love EJ, Memore L, et al. Effect of macrophage stimulation on collagen biosynthesis in the healing wound. Am Surg. 1997;63:125–31.

    CAS  PubMed  Google Scholar 

  35. Leibovich SJ, Danon D. Promotion of wound repair in mice by application of glucan. J Reticuloendothel Soc. 1980;27:1–11.

    CAS  PubMed  Google Scholar 

  36. Torello CO, de Souza Queiroz J, Oliveira SC, Queiroz ML. Immunohematopoietic modulation by oral β-1,3-glucan in mice infected with Listeria monocytogenes. Int Immunopharmacol. 2010;10(12):1573–9.

    Google Scholar 

  37. Sandvik A, Wang YY, Morton HC, Aasen AO, Wang JE, Johansen FE. Oral and systemic administration of beta-glucan protects against lipopolysaccharide-induced shock and organ injury in rats. Clin Exp Immunol. 2007;148(1):168–77.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  38. Zhu W, Gu B, Miao J, Lu J, Zou S. Dectin1 activation of β-(1-3)/(1-6)-d-glucan produces an anti-mastitis effect in rats. Inflamm Res. 2011;60(10):937–45.

    Article  CAS  PubMed  Google Scholar 

  39. Tsukada C, Yokoyama H, Miyaji C, Ishimoto Y, Kawamura H, Abo T. Immunopotentiation of intraepithelial lymphocytes in the intestine by oral administrations of beta-glucan. Cell Immunol. 2003;221(1):1–5.

    Article  CAS  PubMed  Google Scholar 

  40. Bayrak O, Turgut F, Karatas OF, et al. Oral beta-glucan protects kidney against ischemia/reperfusion injury in rats. Am J Nephrol. 2008;28(2):190–6.

    Article  CAS  PubMed  Google Scholar 

  41. Aarsæther E, Straumbotn E, Rösner A, Busund R. Oral β-glucan reduces infarction size and improves regional contractile function in a porcine ischaemia/reperfusion model. Eur J Cardiothorac Surg. 2012;41(4):919–25.

    Article  PubMed  Google Scholar 

  42. Vetvicka V, Vetvickova J. Effects of glucan on immunosuppressive actions of mercury. J Med Food. 2009;12(5):1098–104.

    Article  CAS  PubMed  Google Scholar 

  43. Sener G, Ekşioğlu-Demiralp E, Cetiner M, Ercan F, Yeğen BC. Beta-glucan ameliorates methotrexate-induced oxidative organ injury via its antioxidant and immunomodulatory effects. Eur J Pharmacol. 2006;542(1–3):170–8.

    Article  CAS  PubMed  Google Scholar 

  44. Toklu HZ, Sehirli AO, Velioğlu-Oğünç A, Cetinel S, Sener G. Acetaminophen-induced toxicity is prevented by beta-d-glucan treatment in mice. Eur J Pharmacol. 2006;543(1–3):133–40.

    Article  CAS  PubMed  Google Scholar 

  45. Delatte SJ, Evans J, Hebra A, Adamson W, Othersen HB, Tagge EP. Effectiveness of beta-glucan collagen for treatment of partial-thickness burns in children. J Pediatr Surg. 2001;36(1):113–8.

    Article  CAS  PubMed  Google Scholar 

  46. Medeiros SD, Cordeiro SL, Cavalcanti JE, et al. Effects of purified Saccharomyces cerevisiae (1 → 3)-β-glucan on venous ulcer healing. Int J Mol Sci. 2012;13(7):8142–58.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  47. Talbott S, Talbott J. Effect of BETA 1, 3/1, 6 GLUCAN on upper respiratory tract infection symptoms and mood state in marathon athletes. J Sports Sci Med. 2009;8(4):509–15.

    PubMed Central  PubMed  Google Scholar 

  48. Feldman S, Schwartz HI, Kalman DS, et al. Randomzied phase II clinical trials of Wellmune WGP(R) for immune support during cold and flu season. J Appl Res. 2009;9:30–42.

    CAS  Google Scholar 

  49. Fuller R, Butt H, Noakes PS, Kenyon J, Yam TS, Calder PC. Influence of yeast-derived 1,3/1,6 glucopolysaccharide on circulating cytokines and chemokines with respect to upper respiratory tract infections. Nutrition. 2012;28(6):665–9.

    Article  CAS  PubMed  Google Scholar 

  50. Graubaum HJ, Busch R, Stier H, Gruenwald J. A double-blind, randomized, placebo-controlled nutritional study using an insoluble yeast beta-glucan to improve the immune defense system. Food Nutr Sci. 2012;3:738–46.

    Article  CAS  Google Scholar 

  51. Auinger A, Riede L, Bothe G, Busch R, Gruenwald J. Yeast (1,3)-(1,6)-beta-glucan helps to maintain the body’s defence against pathogens: a double-blind, randomized, placebo-controlled, multicentric study in healthy subjects. Eur J Nutr. 2013;52:1913–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  52. Aarsaether E, Rydningen M, Einar Engstad R, Busund R. Cardioprotective effect of pretreatment with beta-glucan in coronary artery bypass grafting. Scand Cardiovasc J. 2006;40(5):298–304.

    Google Scholar 

  53. Kirmaz C, Bayrak P, Yilmaz O, Yuksel H. Effects of glucan treatment on the Th1/Th2 balance in patients with allergic rhinitis: a double-blind placebo-controlled study. Eur Cytokine Netw. 2005;16(2):128–34.

    Google Scholar 

  54. Redmond HP, Leon P, Lieberman MD, et al. Impaired macrophage function in severe protein-energy malnutrition. Arch Surg. 1991;126(2):192–6.

    Article  CAS  PubMed  Google Scholar 

  55. Agency Response Letter GRAS Notice No. GRN 000239, U.S Food and Drug Administration. http://www.fda.gov/Food/IngredientspackagingLabeling/GRAS/NoticeInventory/ucm153925.htm. Date Accessed 21.12.2013.

  56. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). Scientific opinion on the safety of “yeast betaglucans” as a novel food ingredient. EFSA J. 2011;9:2137.

    Google Scholar 

Download references

Acknowledgments

No funding or sponsorship was received for this study or publication of this article. No writing assistance, other editorial involvement, pharmaceutical involvement, or financial support was provided in the production of this manuscript. Erdinc Yenidogan is the guarantor author for this article and takes full responsibility for the integrity of the work as a whole.

Conflict of interest

Erdinc Yenidogan, Gokhan Giray Akgul, Mehmet Ali Gulcelik, Soykan Dinc, Muhammet Kadri Colakoglu, and Huseyin Ayhan Kayaoglu declare no conflicts of interest.

Compliance with ethics guidelines

All procedures followed were in accordance with the ethical standards of the responsible committee on human Approval was obtained from the ethical committee of Ankara Oncology Training and Research Hospital. The study was conducted in compliance with the Declarations of Helsinki following Good Clinical Practice Guidelines, and was approved by the institutional review board at the study center. The patients who planned to undergo Modified Radical Mastectomy (MRM) with the diagnosis of breast carcinoma between January 2004 and 2010 were enrolled in the study. Written informed consent was obtained from all patients before enrollment.

Author information

Authors and Affiliations

  1. Department of General Surgery, Faculty of Medicine, Gaziosmanpasa University, Tokat, Turkey

    Erdinc Yenidogan & Huseyin Ayhan Kayaoglu

  2. Department of General Surgery, Beypazari City Hospital, Beypazari, Ankara, Turkey

    Gökhan Giray Akgul

  3. Department of General Surgery, Ankara Oncology Training and Research Hospital, Ankara, Turkey

    Mehmet Ali Gulcelik, Soykan Dinc & Muhammet Kadri Colakoglu

Authors
  1. Erdinc Yenidogan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gökhan Giray Akgul
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mehmet Ali Gulcelik
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Soykan Dinc
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Muhammet Kadri Colakoglu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Huseyin Ayhan Kayaoglu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Erdinc Yenidogan.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (PDF 201 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yenidogan, E., Akgul, G.G., Gulcelik, M.A. et al. Effect of β-Glucan on Drain Fluid and Amount of Drainage Following Modified Radical Mastectomy. Adv Ther 31, 130–139 (2014). https://doi.org/10.1007/s12325-014-0091-2

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12325-014-0091-2

Keywords

Search

Navigation